PortfoliosLab logo

Akari Therapeutics, Plc (AKTX)

Equity · Currency in USD · Last updated Dec 9, 2022

Company Info

ISINUS00972G1085
CUSIP00972G108
SectorHealthcare
IndustryBiotechnology

Trading Data

Previous Close$0.53
Year Range$0.40 - $1.59
EMA (50)$0.60
EMA (200)$0.93
Average Volume$82.03K
Market Capitalization$32.64M

AKTXShare Price Chart


Loading data...

AKTXPerformance

The chart shows the growth of $10,000 invested in Akari Therapeutics, Plc in May 2013 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $21 for a total return of roughly -99.79%. All prices are adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%40.00%60.00%JulyAugustSeptemberOctoberNovemberDecember
-47.50%
5.70%
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)

AKTXCompare to other instruments

Search for stocks, ETFs, and funds to compare with AKTX

AKTXReturns in periods

Returns over 1 year are annualized

PeriodReturnBenchmark
1M8.14%4.12%
6M-50.94%-3.70%
YTD-64.67%-16.84%
1Y-65.37%-15.43%
5Y-36.00%8.20%
10Y-50.82%10.24%

AKTXMonthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2022-8.67%-1.46%-11.11%-0.83%-1.68%-14.53%14.00%4.39%-47.06%-26.03%18.67%-4.18%
202136.76%32.41%-21.19%-21.97%-12.86%-3.62%-6.36%13.58%-11.41%1.84%-1.81%-7.98%
20202.86%2.22%-21.20%32.41%6.25%6.86%-7.80%-14.43%1.16%-13.79%6.67%15.62%
201928.01%-9.94%97.79%0.00%-46.93%6.32%-6.93%10.64%-17.79%11.11%8.42%-15.05%
2018-33.95%-31.82%-6.67%4.95%-3.66%5.98%-1.54%-2.08%36.17%-29.69%-0.56%-12.29%
201713.64%-18.63%70.05%35.41%-59.11%-24.80%0.87%-23.66%72.96%-30.13%13.29%-10.91%
2016-4.57%-30.19%44.93%22.86%-12.21%-10.66%-31.06%1.72%-10.04%11.05%-24.34%-1.54%
201520.83%-84.48%-15.56%-1.32%-41.56%32.33%-1.72%347.37%-5.90%-20.40%1.57%-25.25%
201425.35%-27.53%0.62%-6.01%-16.39%21.57%-8.71%4.24%3.39%-2.95%-10.14%-9.77%
2013-5.00%-15.79%0.00%0.00%0.00%0.00%-50.00%-29.00%

AKTXSharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Akari Therapeutics, Plc Sharpe ratio is -0.89. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.


-1.00-0.80-0.60-0.40-0.20JulyAugustSeptemberOctoberNovemberDecember
-0.89
-0.65
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)

AKTXDividend History


Akari Therapeutics, Plc doesn't pay dividends

AKTXDrawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%2022FebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember
-99.79%
-17.37%
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)

AKTXWorst Drawdowns

The table below shows the maximum drawdowns of the Akari Therapeutics, Plc. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Akari Therapeutics, Plc is 99.84%, recorded on Oct 24, 2022. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.84%May 23, 20132153Oct 24, 2022

AKTXVolatility Chart

Current Akari Therapeutics, Plc volatility is 76.41%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.


0.00%50.00%100.00%150.00%JulyAugustSeptemberOctoberNovemberDecember
76.41%
23.44%
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)